SB
BMRN icon

Strategic Blueprint’s BioMarin Pharmaceuticals BMRN Stock Holding History

Strategic Blueprint’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9
Closed -$1K – 505
2021
Q2 		$1K Buy
+9
New +$713 ﹤0.01% 1284

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Strategic Blueprint's BMRN Position: Q3 2021 in Review

Strategic Blueprint sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 9 shares — an estimated $1K sold.

Strategic Blueprint first reported a position in BMRN in Q2 2021 and held it in 1 quarter. The position peaked at $1K in Q2 2021. 511 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

  • Strategic Blueprint reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Strategic Blueprint sold 9 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $1K.
  • Strategic Blueprint first reported a position in BioMarin Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Strategic Blueprint's BioMarin Pharmaceuticals position peaked at $1K in Q2 2021.
  • 511 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Strategic Blueprint's 13F filing for Q3 2021, filed 12 Nov 2021.